Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

Neurology

Volumn 77, Issue 9, 2011, Pages 835-843

  Hartung, H P ^a   Freedman, M S ^b   Polman, C H ^c   Edan, G ^d   Kappos, L ^e   Miller, D H ^f   Montalb An X ^g   Barkhof, F ^c   Petkau, J ^h   White, R ^h   Sahajpal, V ^i,j   Knappertz, V ^a   Beckmann, K ^k   Lanius, V ^k   Sandbrink, R ^a,k   Pohl, C ^k  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF OTTAWA   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ PAREXEL INTERNATIONAL   (United States)

^j BAYER CORPORATION   (United States)

^k BAYER PHARMA AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INTERFERON BETA 1B NEUTRALIZING ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; BETA INTERFERON;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DEMYELINATING DISEASE; FOLLOW UP; IMMUNOLOGY; LONGITUDINAL STUDY; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, NEUTRALIZING; CROSS-SECTIONAL STUDIES; DEMYELINATING DISEASES; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES;

EID: 80055068683     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822c90d7     Document Type: Article

References (40)

1. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(suppl 2):4-9.
2. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-215.
3. Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
4. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 2004; 127:259-268. (Pubitemid 38160311)
5. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243. (Pubitemid 29177928)
6. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-377.
7. Interferon Beta MS Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
8. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-1272. (Pubitemid 28240338)
9. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
10. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002; 359:1453-1460. (Pubitemid 34457761)
11. Panitch H, Goodin DS, Francis G. Randomized, comparative study of interferon-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506. (Pubitemid 35387053)
12. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of beta interferon during treatment of multiple sclerosis. Neurology 2004;62:2031-2037. (Pubitemid 38738217)
13. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon-1a: a 4-year controlled study. Neurology 2005;65:40-47. (Pubitemid 40967774)
14. Sominanda A, Rot U, Suoniemi M, et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.Mult Scler 2007;13:208-214. (Pubitemid 46592773)
15. Sørensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39. (Pubitemid 40967773)
16. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-138. (Pubitemid 38499903)
17. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279. (Pubitemid 29177937)
18. Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215:3-8. (Pubitemid 37272189)
19. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Neurology 2007;68:977-984.
20. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56: 1628-1636.
21. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon-1b. Neurology 2003;60:37-43. (Pubitemid 36070641)
22. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
23. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249. (Pubitemid 44563835)
24. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397. (Pubitemid 47189673)
25. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231. (Pubitemid 13158528)
26. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024. (Pubitemid 29011608)
27. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001;21:743-755. (Pubitemid 32955704)
28. Sørensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191. (Pubitemid 37255344)
29. Goodin DS, Arnason BGW, Comi G, et al. Neutralizing antibodies during treatment with interferon beta-1b in 1745 patients with relapsing-remitting multiple sclerosis. Neurology 2009;72(suppl 3):A317-A318.
30. Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007;35: 173-187. (Pubitemid 46831066)
31. Rot U, Sominanda A, Fogdell-Hahn A, Hillert J. Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status. J Int Med Res 2008;36: 1418-1425.
32. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-245. (Pubitemid 34596884)
33. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006; 59:597-605.
34. Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsingremitting MS patients. Neurology 2002;58:417-421. (Pubitemid 34150916)
35. Tintore M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-972. (Pubitemid 44454586)
36. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006;60:236-242. (Pubitemid 44182398)
37. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis Lancet 1999;353:964-969. (Pubitemid 29132605)
38. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705-711.
39. Gibbs E, Oger J. The IgG subclass-specificities of anti- IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol 2007;190:146-150. (Pubitemid 47625609)
40. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFNβ antibodies on MRI patients in the BECOME study. Neurology 2009;73:1485-1492.